Form 4: Bionano Genomics General Counsel Reports Tax Withholding Share Transaction

Sentiment:

SEC Form 4 Filing


Jonathan V. Dixon, General Counsel of Bionano Genomics, reports the withholding of 402 shares to cover tax obligations related to a vested RSU award.

Summary

  • On February 15, 2024, Jonathan V. Dixon, General Counsel of Bionano Genomics, had 402 shares of common stock withheld by the issuer to satisfy tax obligations.
  • These shares were related to an RSU award that vested on the same date, February 15, 2024, and was granted on February 15, 2023.
  • Following this transaction, Dixon directly owns 3,525 shares of Bionano Genomics common stock.
  • A previous 1-for-10 stock split on August 4, 2023, resulted in Dixon owning 35,343 fewer shares.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to tax obligations on vested stock awards. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are routine and provide transparency to the market regarding insider transactions.

Key Dates

DateDescription
February 15, 2023Date of RSU award grant
August 4, 20231-for-10 stock split date
February 15, 2024Date of RSU vesting and tax withholding of 402 shares
March 05, 2024Date of Form 4 filing

Keywords

Bionano Genomics, BNGO, Form 4, Jonathan V. Dixon, General Counsel, RSU, Tax Withholding, Stock Split, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.